Association between IL28B polymorphisms and outcome of treatment for acute hepatitis C in HIV-patients

Association between IL28B polymorphisms and outcome of treatment for acute hepatitis C in HIV-patients - IL28B NSP in acute HCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34931

Enrollment

Registered

2010-05-26

Start date

2010-06-16

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IL28B single nucleotide polymorfism (SNP) IL28B substitution

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: all HIV-infected patients seen at the two outpatient clinics (UMCU and UMCG) (having been) treated with peginterferon-alfa mono-therapy for acute HCV.

Exclusion criteria

Exclusion criteria: none, it's a excisting cohort of 19 treated patients with acute HCV and HIV

Design outcomes

Primary

Measure	Time frame
Association between IL28B SNPs and outcome of acute HCV treatment.	—

Countries

Netherlands

Outcome results